A two-stage genome-wide association study to identify novel genetic loci associated with acute radiotherapy toxicity in nasopharyngeal carcinoma

Yang Wang1,2,3,4, Fan Xiao1,2,3,4, Yi Zhao1,2,3,4,5, Chen-Xue Mao1,2,3,4, Lu-Lu Yu1,2,3,4, Lei-Yun Wang1,2,3,4, Qi Xiao1,2,3,4, Rong Liu1,2,3,4, Xi Li1,2,3,4, Howard L. McLeod1,2,3,4,6,7, Bi-Wen Hu8, Yu-Ling Huang9,10, Qiao-Li Lv9,10, Xiao-Xue Xie11, Wei-Hua Huang1,2,3,4, Wei Zhang1,2,3,4, Cheng-Xian Guo8*, Jin-Gao Li9,10* and Ji-Ye Yin1,2,3,4,12*

Abstract

Background: Genetic variants associated with acute side effects of radiotherapy in nasopharyngeal carcinoma (NPC) remain largely unknown.

Methods: We performed a two-stage genome-wide association analysis including a total of 1084 patients, where 319 individuals in the discovery stage were genotyped for 688,783 SNPs using whole genome-wide screening microarray. Significant variants were then validated in an independent cohort of 765 patients using the MassARRAY system. Gene mapping, linkage disequilibrium, genome-wide association analysis, and polygenic risk score were conducted or calculated using FUMA, LDBlockShow, PLINK, and PRSice software programs, respectively.

Results: Five SNPs (rs6711678, rs4848597, rs4848598, rs2091255, and rs584547) showed statistical significance after validation. Radiotherapy toxicity was more serious in mutant minor allele carriers of all five SNPs. Stratified analysis further indicated that rs6711678, rs4848597, rs4848598, and rs2091255 correlated with skin toxicity in patients of EBV positive, late stage (III and IV), receiving both concurrent chemoradiotherapy and induction/adjuvant chemotherapy, and with OR values ranging from 1.92 to 2.66. For rs584547, high occurrence of dysphagia was found in A allele carriers in both the discovery (\(P = 1.27 \times 10^{-6}\), OR = 1.55) and validation (\(P = 0.002\), OR = 4.20) cohorts. Furthermore, prediction models integrating both genetic and clinical factors for skin reaction and dysphagia were established. The area under curve (AUC) value of receiver operating characteristic (ROC) curves were 0.657 (skin reaction) and 0.788 (dysphagia).

Conclusions: Rs6711678, rs4848597, rs4848598, and rs2091255 on chromosome 2q14.2 and rs584547 were found to be novel risk loci for skin toxicity and dysphagia in NPC patients receiving radiotherapy.

*Correspondence: gchxyy@163.com; lijingao@hotmail.com; yinjiye@csu.edu.cn

1 Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410078, P. R. China
2 Center of Clinical Pharmacology, the Third Xiangya Hospital, Central South University, Changsha 410013, Hunan, P. R. China
3 Department of Radiation Oncology, Jiangxi Cancer Hospital of Nanchang University, Nanchang 330029, P.R. China
4 Full list of author information is available at the end of the article

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Introduction
Nasopharyngeal carcinoma (NPC) is an epithelial malignant tumor arising from the lining of nasopharynx [1]. The incidence of NPC has a unique geographical distribution pattern, with Chinese patients accounting for approximately 50% of all patients. In China, NPC mainly occurs in southern regions, including Hunan, Jiangxi, Guangxi, Guangdong, and Fujian provinces [2]. The main treatment methods for NPC include radiotherapy, chemotherapy, and immunotherapy. Among these, radiotherapy has an important role. However, side effects, which can be divided into acute and late toxicity according to the occurrence of time point, are common and serious. Late toxicity is generally a toxic reaction occurring within 1 to 3 years after the end of radiotherapy, while acute toxicity occurs within 3 months. Almost half of the patients reportedly suffer acute grade 2–3 toxicities, including oral mucositis, skin reaction, dysphagia, neutropenia, etc. [3]. Although some toxicities could be relieved after supportive care measures, they could be associated with lingering morbidity or even death [4]. Thus, it is important to discover the contributors of acute radiotherapy toxicity for NPC patients and explore their prediction performance in the clinic.

Radiogenomics aims to identify genetic variants contributing to radiotherapy effects and toxicity [3]. Over the past decade, the genome-wide association study (GWAS) has emerged as one of the major strategies for radiogenomic investigation and has successfully identified some genetic variants associated with radiation toxicity in cancers of the prostate, breast, cervix, and lung [3, 5–7]. For NPC, radiogenomic studies employing GWAS to identify susceptibility loci for radiotherapy toxicity are still limited. Some genetic variants were found to be involved in the development of neurotoxicity and oral mucositis [8, 9]. For other acute toxicities, a study used as the main method sample candidate gene association in a small sample size. Genetic variants associated with radiation-induced dysphagia, skin reaction salivary gland toxicity, and myelosuppression still largely remain unknown.

In this study, we performed a two-stage GWAS study using a total of 1084 NPC patients that aimed to discover the genetic variants associated with radiotherapy acute toxicity and evaluate their clinic prediction performance.  

Methods
Study population and data collection
All patients in this study were recruited from Jiangxi Province Tumor Hospital (Nanchang, Jiangxi, China) and Hunan Cancer Hospital (Changsha, Hunan, China), from October 2014 to December 2017. Patients were diagnosed with NPC by histopathological examination and treated by intensity modulated radiation therapy (IMRT) with 6-MV photons at a dose of 2 Gy/d, 5 times a week. The prescribed doses were calculated according to the gross tumor volume (GTV), clinical target volume (CTV), and planning target volume (PTV). Primary lesions and positive cervical lymph nodes received 66–77 Gy and 54–60 Gy in 30–33 fractions, respectively. A platinum-based regimen was used as induction, adjuvant, or concurrent chemoradiotherapy. Patients did not undergo surgery, targeted therapy, immunotherapy, or other anti-tumor therapy before radiotherapy. Patients with serious concomitant diseases that might greatly affect their physical condition were excluded.

A physical examination as well as a detailed inquiry into each patient’s medical history was carried out. Acute radiotherapy toxicities were evaluated based on criterion of the Radiation Therapy Oncology Group or European Organization for Research and Treatment of Cancer (RTOG/EORTC) [10]. Based on this scoring criteria, grade 0 was absent of toxicities, while grade 5 signified the death of patients. Grade 1–4 represented increasing severity of toxicities. In the present study, skin reaction, dysphagia, oral mucositis, salivary gland toxicity, and myelosuppression were evaluated. For the association analysis, all patients were further divided into two groups: mild (grade 0 and 1) and moderate/severe toxicity (grade 2 and 3), since no grade 4 and 5 toxicities were found. It should be noted that patients were divided into two groups based on the presence or absence of toxicity for myelosuppression, since few patients had moderate or severe toxicities (grades 2–5). Therapeutic responses of all patients were assessed according to response evaluation criteria in solid tumors (RECIST) 1.1 version [11]. Patients with a complete response (CR) or a partial response (PR) were defined as responders. Patients showing stable disease (SD) or progressive disease (PD) were defined as non-responders.

The study protocol was approved by the Ethics Committee of Jiangxi Province Tumor Hospital and Hunan...
Cancer Hospital. All patient information and data from both hospitals were collected using the same protocol, and there was no overlap of patients. All subjects were provided with written informed consents. We applied this study for clinical admission in the Chinese Clinical Trial Register (registration number: ChiCTR-OPC-14005257). As indicated in Fig. 1A, this was a two-stage GWAS study. A total of 1426 patients were initially enrolled, 345 patients were excluded due to absence of toxicity assessment, failed DNA quality control, or failed genotyping quality control. Ultimately, 1084 patients were included in the two-stage analysis.

Genotyping, quality control, and whole genome imputation
The detailed process of GWAS analysis, bioinformatic tools utilized, and their parameters in this study are summarized in Fig. S1. In brief, genotyping was performed using the Global Screening Array-24 v1.0 BeadChip (Illumina, San Diego, CA, USA) for 688,783 SNPs. Genotype calls were determined using GenomeStudio software from Illumina (San Diego, CA, USA). The systematic quality control was performed on the raw genotyping data to filter both unqualified samples and SNPs using PLINK (1.9 version). After sample relatedness, heterozygosity and sex check, samples were excluded if they failed genotyping in more than 10% of variants. SNPs were excluded if: (1) SNPs were not mapped on autosomal chromosomes; (2) SNPs had a call rate < 95%; (3) SNPs had MAF < 0.05; or (4) SNPs deviated significantly from Hardy-Weinberg equilibrium (HWE) ($P < 1 \times 10^{-5}$). IMPUTE2 was used to perform phasing and imputation on the filtered un-phased genotypes to impute un-typed SNPs based on 1000 Genomes Phase 3 v4 reference [12]. Imputed genotypes with IMPUTE2 info lower than 0.4 were discarded for association analysis and SNPs that had MAF < 0.05 were further excluded. Finally, a total of 4,112,760 unique SNPs were included in the GWAS analysis. In the validation stage, SNP genotyping was performed using the Sequenom MassARRAY system (Sequenom, San Diego, CA, USA) according to the manufacturer’s instructions. The exclusion criteria included: (1) After sample relatedness, heterozygosity and sex check, samples that failed genotyping in more than 10% of variants; (2) SNPs that had a call rate < 90%; (3) SNPs that had MAF < 0.05; or (4) SNPs that deviated significantly from Hardy-Weinberg equilibrium (HWE).

Genome-wide association analysis
In the discover stage, principal component analysis (PCA) was performed using data from all patients using PLINK (1.9 version) program (Fig. S2) [13]. The genomic inflation factor of population stratification $\lambda$ was also calculated by PLINK (1.9 version). The chi square test was employed to evaluate the association between clinical factors and various toxicities. The significantly associated factors were considered covariates. For five phenotypes of skin reaction--dysphagia, oral mucositis, salivary gland toxicity, and myelosuppression--GWAS was conducted under the additive, dominant, and recessive models by multivariate logistic regression analysis, adjusted by age, sex, body mass index (BMI), smoking status, stage, Epstein-Barr virus (EBV) infection, and radiotherapeutic regimen as covariates.

Bioinformatics and statistical analysis
The linkage disequilibrium (LD) and haplotype block estimation analyses were performed using PLINK (1.9 version) and LDBlockShow (1.35 version). Regional plots and gene mapping were generated using the online tool LocusZoom (http://locuszoom.sph.umich.edu/) and functional mapping and annotation (FUMA) v1.3.4c (https://fuma.ctglab.nl/) [14, 15]. Transcription regulation was predicted based on the data of ENCODE database (https://www.encodeproject.org/) [16]. The polygenic risk score was calculated and evaluated by PRSice-2 v2.3.5 [17]. All other statistical analyses were performed using SPSS 20.0 software (SPSS Inc., Chicago, Illinois, USA). In this study, all $P$-values were two-sided and $P \leq 0.05$ was considered to be statistically significant.

Results
Clinical characteristics
This two-stage genome-wide association study involved a total of 1084 subjects. Among them, a total of 319 patients from Jiangxi Province Tumor Hospital were recruited into the discovery stage cohort, and 765 patients from Hunan Cancer Hospital were used to validate the results. Table 1 summarizes the demographic characteristics of all patients. The whole-genome microarray analysis was performed on peripheral blood DNA samples from 319 patients in the discovery stage. After quality control and genotype imputation, a total of 4,112,760 SNPs passed quality screening and were included in the association analysis.

In the discovery stage of this study, five acute radiotherapy toxicities of skin reaction, dysphagia, oral mucositis, salivary gland toxicity, and myelosuppression were investigated. The characteristics of NPC patients involved in these association analyses are summarized in Tables S1, S2, S3, S4 and S5. For each phenotype, the association of clinical characteristics of age, gender, BMI, smoking status, EBV infection, clinical stage, and treatment scheme between different subgroups was analyzed. All significant clinical factors were considered as covariates and adjusted in subsequent GWAS analysis.
Fig. 1 Genome-wide association study design and results in discovery cohort. A Flow diagram of clinical study design. B-E Manhattan plot showed the genome-wide association results for skin reaction (A), dysphagia (B), oral mucositis (C), salivary gland toxicity (D), and myelosuppression (E). SNPs successfully validated in the validation cohort are indicated. Association $P$ values are expressed as $-\log_{10}(p)$. $P$ values were calculated from multivariate logistic regression analysis.
**Table 1** Characteristics of all patients

| Characteristics             | Discovery stage | Validation stage |
|-----------------------------|-----------------|------------------|
| Number of patients          | 319             | 765              |
| Age (Mean ± SD)             | 50.75 ± 11.96   | 48.30 ± 9.87     |
| Gender                      |                 |                  |
| Male                        | 215             | 570              |
| Female                      | 104             | 195              |
| BMI (Mean ± SD)             | 22.61 ± 3.40    | 23.16 ± 3.30     |
| Smoking status              |                 |                  |
| Smoker                      | 149             | 372              |
| Non-smoker                  | 166             | 370              |
| NR                          | 4               | 23               |
| Clinical stage              |                 |                  |
| I                           | 7               | 19               |
| II                          | 26              | 64               |
| III                         | 120             | 325              |
| IV                          | 165             | 307              |
| NR                          | 1               | 50               |
| EBV                         |                 |                  |
| Positive                    | 216             | 408              |
| Negative                    | 103             | 311              |
| NR                          | 0               | 46               |
| Treatment scheme            |                 |                  |
| RT alone                    | 60              | 12               |
| RT + IC/AC                  | 4               | 0                |
| CCRT                        | 100             | 26               |
| CCRT + IC/AC                | 154             | 606              |
| RT + other treatmenta       | 1               | 121              |

**SD** Standard deviation, **BMI** Body mass index, **EBV** Epstein-Barr virus, **NR** Not reported, **RT** Radiotherapy, **IC** Induction chemotherapy, **AC** Adjuvant chemotherapy, **CCRT** Concurrent chemoradiotherapy

*Other treatment included surgery, targeted therapy, immunotherapy and herbs treatment

**GWAS analysis for five toxicities**

For GWAS analysis, a quantile-quantile plot was created to evaluate the data quality (Fig. S3). Deviation from the expected $P$ value distribution was evident only in the tail region. For the results of the association analysis, the genomic inflation factor $\lambda$ was 0.971, 1.017, 0.989, 0.976, and 0.981 for skin reaction, dysphagia, oral mucositis, salivary gland toxicity, and myelosuppression, respectively. In addition, PCA results showed that no stray samples appeared in any toxicity (Fig. S2). The results also indicated that the patient population was ethnically homogeneous, and the observed associations were not driven by potential population substructure. Thus, no principal components (PC) were incorporated as covariates in the following association analysis. The Manhattan plot in Fig. 1B–E shows the results of five toxicities in discovery stage. Variations with $P < 1 \times 10^{-5}$ (dysphagia, oral mucositis, salivary gland toxicity, and myelosuppression) or $P < 1 \times 10^{-5.5}$ (skin reaction) were selected for MassArray genotyping in the validation stage samples. As indicated in Table 2, a total of 16 SNPs were finally successfully genotyped. For myelosuppression, no SNPs satisfied the quality control criteria in the validation cohort, rendering this phenotype incompletely assessed. For oral mucositis and salivary gland toxicity, no SNPs were successfully replicated as being associated with the specific toxicity in the validation cohort. Finally, five SNPs were successfully validated by showing statistical significance.

Rs6711678, rs4848597, rs4848598, and rs2091255 correlated with skin reaction. These four SNPs were all located on the chromosome 2q14.2 and showed high LD with each other. They showed similar $P$ and OR value in both the discovery ($P$ value ranged from $4.82 \times 10^{-7}$ to $9.83 \times 10^{-7}$, OR value ranged from 1.23 to 1.40) and validation cohort ($P$ value ranged from 0.007 to 0.014, OR value ranged from 1.42 to 1.48) for the minor allele. In addition, rs584547 was identified to be associated with high occurrence of dysphagia for A allele in both the discovery ($P = 1.27 \times 10^{-6}$, OR = 1.55) and validation ($P = 0.002$, OR = 4.20) cohort. Thus, these five SNPs underwent further analysis.

**Stratified and meta-analysis of five associated variants**

As previously reported, clinical factors may also contribute to drug or radiotherapy toxicities [18, 19]. Therefore, we conducted stratified analysis for these five SNPs in the combined cohort. Clinical characteristics only showed significant influence on the genetic correlation of rs6711678, rs4848597, rs4848598, and rs2091255. Thus, these SNPs were further analyzed. As indicated in Table S6, for smoking status, the association existed in both smokers and non-smokers. However, for EBV infection, clinical stage, and treatment scheme, the association only existed in subgroups of EBV positive, late stage (III and IV), and patients receiving both concurrent chemoradiotherapy and induction/adjuvant chemotherapy. This result indicated that clinical factors might affect the results of radiotherapy toxicity analysis. For example, half of EBV positive patients who were homozygous mutant for these four SNPs also experienced grade 2 or 3 skin toxicity after receiving radiotherapy. In contrast, this ratio was less than 25% in the wild-type patients.

Based on these findings, we considered that rs6711678, rs4848597, rs4848598, and rs2091255 were more associated with skin reaction in NPC patients who were EBV positive, late stage (III and IV), and receiving both concurrent chemoradiotherapy and induction/adjuvant chemotherapy. We thus further conducted the association analysis in this subgroup. As indicated in Table 3, the results are consistent in three
different models for all SNPs. Minor allele carriers showed higher risk of skin reaction with an OR value increasing to more than 2. Figure 2 supports this result more intuitively by calculating the patients with different grades of toxicities in groups of three genotypes. For all SNPs, occurrence of grade 2 and 3 skin reaction toxicities remarkably increased in minor allele carriers. In contrast, mild toxicity (grade 1) dramatically decreased. We next performed therapeutic response analysis in these patients and observed that there were more non-responders in patients with minor alleles for all four SNPs, with an OR value ranging from 1.92 to 2.66 (Table S7).

Table 2 The SNPs associated with acute radiotherapy toxicity in nasopharyngeal carcinoma patients

| CHR | SNPs | Gene | Allele | MAF  | Discovery stage | Validation stage |
|-----|------|------|--------|------|----------------|-----------------|
|     |      |      |        |      | P value | OR   | P value | OR   |
| Skin reaction | 2 | rs6711678 | INHBB | G/C | 0.28 | 7.17 x 10^{-7} | 1.23 | 0.009 | 1.46 |
| 2 | rs4848597 | INHBB | C/T   | 0.30 | 4.82 x 10^{-7} | 1.34 | 0.014 | 1.42 |
| 2 | rs4848598 | INHBB | G/A   | 0.28 | 4.91 x 10^{-7} | 1.36 | 0.010 | 1.45 |
| 2 | rs2091255 | INHBB | G/T   | 0.24 | 9.83 x 10^{-7} | 1.40 | 0.007 | 1.48 |

Dysphagia

| 5 | rs670902 | MGAT1 | T/C | 0.40 | 6.71 x 10^{-6} | 1.98 | 0.656 | 0.75 |
| 9 | rs149372542 | None | G/A | 0.18 | 5.13 x 10^{-6} | 1.03 | 0.250 | 1.82 |
| 11 | rs584547 | SYT8 | G/A | 0.27 | 1.27 x 10^{-6} | 1.55 | 0.002 | 4.20 |
| 11 | rs111570505 | None | A/G | 0.19 | 1.41 x 10^{-6} | 0.40 | 0.212 | 1.86 |
| 12 | rs14143 | BR3BP | G/A | 0.49 | 5.18 x 10^{-6} | 0.99 | 0.521 | 1.36 |

Oral mucositis

| 5 | rs10214299 | EDIL3 | A/C | 0.47 | 3.79 x 10^{-6} | 0.93 | 0.984 | 1.00 |
| 6 | rs1334970 | SLC25A27 | T/C | 0.30 | 2.04 x 10^{-6} | 1.45 | 0.524 | 1.12 |
| 12 | rs4766031 | TSPAN9 | G/A | 0.42 | 1.41 x 10^{-6} | 0.96 | 0.662 | 0.94 |
| 6 | rs11754905 | SLC25A27 | C/T | 0.31 | 2.00 x 10^{-6} | 0.69 | 0.705 | 1.07 |

Salivary glands toxicity

| 10 | rs73328964 | ASAH2 | T/C | 0.05 | 5.51 x 10^{-6} | 1.65 | 0.719 | 1.16 |
| 10 | rs73328981 | ASAH2 | C/T | 0.05 | 5.51 x 10^{-6} | 1.13 | 0.515 | 1.51 |
| 22 | rs35806646 | RASD2 | T/C | 0.14 | 3.28 x 10^{-6} | 1.35 | 0.719 | 1.16 |

was analyzed in the combined cohort without any stratification. Due to the limited number, AA genotypes were combined in analysis with AG heterozygote patients. As indicated in Fig. 2, grade 3 toxicity occurred more in the A allele carriers, while all other grade toxicities were decreased. Higher resistance to the radiotherapy was also found in these patients.

Toxicity prediction models

Based on above analysis, the toxicity was increased, and response was decreased in minor allele carriers for all five SNPs, which could be considered as potential biomarkers for precision radiotherapy of NPC patients. We thus evaluated their toxicity prediction performance. For skin reaction toxicity and dysphagia, the combined cohort

Table 3 Association between skin reaction and chromosome 2q14.2 loci in the stratified patients

| SNP    | MAF  | Additive P value | OR (95%CI) | Dominant P value | OR (95%CI) | Recessive P value | OR (95%CI) |
|--------|------|------------------|------------|------------------|------------|-------------------|------------|
| rs6711678 | 0.30 | 1.15 x 10^{-3} | 1.79 (1.26-2.55) | 4.54 x 10^{-3} | 2.00 (1.24-3.22) | 0.03 | 2.24 (1.08-4.64) |
| rs4848597 | 0.31 | 1.93 x 10^{-3} | 1.74 (1.22-2.47) | 7.21 x 10^{-3} | 1.92 (1.19-3.09) | 0.03 | 2.22 (1.07-4.59) |
| rs4848598 | 0.30 | 6.32 x 10^{-4} | 1.84 (1.30-2.63) | 2.85 x 10^{-3} | 2.07 (1.28-3.33) | 0.02 | 2.37 (1.13-4.95) |
| rs2091255 | 0.29 | 7.16 x 10^{-4} | 1.83 (1.29-2.61) | 3.89 x 10^{-3} | 2.01 (1.25-3.22) | 0.02 | 2.48 (1.18-5.24) |
patients were first randomly divided into two groups, which were used to establish and test models, respectively. The sample size of each group accounted for 50% of all patients. Three multivariable logistic regression models were established: with genetic factors only, clinical factors only, and a combination of both genetic and clinical factors. For skin reaction toxicity, four SNPs of rs6711678, rs4848597, rs4848598, and rs2091255 were combined as polygenic risk scores in the genetic-only model after controlling clinical parameters. As indicated in Fig. S4, the area under curve (AUC) value of receiver operating characteristic (ROC) curves of the genetic-only model was larger than that of clinical-only model in both groups for all phenotypes. This result suggested that the genetic model integrating four SNPs was more accurate in classifying skin reaction occurrence patients compared with estimating using only clinical characteristics. After further integrating clinical factors, the ROC AUC of the combined model further increased. The similar performance of each model in both establishing and testing groups supported the reliability of our models. Therefore, we established the final prediction models for two toxicities in the combined cohort. As indicated in Fig. 3A, the ROC AUCs of genetic only, clinical only, and combined factors for skin reaction toxicity were 0.632, 0.577, and 0.657, respectively. The performance was better for dysphagia, where the corresponding values were 0.721, 0.688, and 0.788, respectively (Fig. 3B). These results together showed that these five genetic variants could potentially be used to predict skin reaction and dysphagia toxicities in NPC patients receiving radiotherapy.

Gene mapping
To learn the functional consequences of the five risk loci, we mapped them to genes. As indicated in Fig. 4, rs6711678, rs4848597, rs4848598, and rs2091255 were closely located on the chromosome 2q14.2, spanning only 1690 bp. Further analysis showed that all four SNPs were in strong LD in the genome. Although they were closer to a long non-coding RNA (LncRNA) of LINC01101, eQTL analysis implicated genes of inhibin subunit beta B (INHBB). In addition, 3D chromatin interaction indicated that they interacted with transcription factor CP2

Fig. 2 Patient distribution in different genotypes according to skin reaction toxicity (A) and radiotherapeutic response (B). For 2q14.2 loci, all patients were EBV positive, late stage (III and IV), and receiving both concurrent chemoradiotherapy and induction/adjuvant chemotherapy. For rs584547, AA genotypes were combined in analysis with AG heterozygote patients due to the limited number
like 1 (TFCP2L1) and protein tyrosine phosphatase non-receptor type 4 (PTPN4).

The SNP rs584547 localized very closely upstream of synaptotagmin-8 (SYT8). However, LD analysis showed that it was not in linkage with any proximal SNPs (Fig. 4D). 3D chromatin interaction and eQTL analysis also showed no implicated genes. Considering 5′ upstream SNPs may affect gene expression by altering promoter activity, we evaluated its transcription regulation function using ENCODE database. The result suggested that rs584547 showed a proximal transcriptional regulation function on SYT8 gene.

Discussion

In the current study, we explored the genetic variants associated with radiotherapy acute toxicity of skin reaction, dysphagia, oral mucositis, salivary gland toxicity, and myelosuppression, using GWAS in a total of 1084 NPC patients. Chromosome 2q14.2 loci (rs6711678, rs4848597, rs4848598, and rs2091255) and rs584547 were found to be significantly associated with skin reaction and dysphagia. The toxicities were more serious in minor allele carriers. Further stratified analysis showed that chromosome 2q14.2 loci correlated with skin reaction in patients that were EBV positive, late stage (III and IV), and receiving both concurrent chemoradiotherapy and induction/adjuvant chemotherapy. The area under curve (AUC) values of receiver operating characteristic (ROC) curves of prediction models integrating both genetic and clinical factors for skin reaction and dysphagia were 0.657 and 0.788, respectively. The mapped genes were INHBB, TFCP2L1, and PTPN4 for 2q14.2 loci, and SYT8 for rs584547.

Radiotherapy is the main treatment method for NPC. However, severe acute side effects often occur in the pharynx, mucous membranes, skin, or hematopoietic system and significantly affect the therapeutic results and quality of life. Previous reports observed that some genetic variants correlated with these toxicities, including X-ray repair cross complementing 1 (XRCC1), XRCC3, XRCC6, transforming growth factor beta 1 (TGFβ1), etc. [20, 21]. However, these studies mainly used candidate gene association strategy, with a focus on DNA repair genes. More genetic variants remain to be discovered. Since GWAS provides a powerful strategy to discover novel genetic variants, we conducted this current study to identify novel genetic variants associated with acute radiotherapy toxicity in NPC patients. After validating in an independent cohort from another hospital, we finally found that chromosome 2q14.2 loci (rs6711678, rs4848597, rs4848598, and rs2091255) and rs584547 were
associated with skin reaction and dysphagia. These loci were novel and had not been reported in either NPC or other cancers. Previous studies have identified some loci associated with similar radiation-induced toxicities, including rs35542, rs117157809, and NBN (nibrin) variants [22, 23]. However, these loci did not show significant correlation in our study. We speculated that the main reasons were different phenotypes and population. Considering that we discovered these SNPs in the Chinese patients, we explored their ethnic differences by comparing the MAF in six major populations. As indicated in Fig. S5, all five SNPs showed significant ethnic differences. This could be one of the potential reasons of inconsistence results between our studies and others.

Skin reaction is a common toxicity of radiotherapy in both NPC and other cancers; therefore, it attracts great attention. Several studies reported the correlation of genetic variants and skin reaction. However, these studies mainly investigated breast cancer patients using candidate gene association study strategies [24–28]. Polymorphisms of XRCC1 were the most widely investigated. The results contradicted each other [29]. For NPC, little is known about the genetic variants that correlate with skin toxicities. We found that four novel genetic loci on chromosome 2q14.2 correlated with susceptibility of radiotherapy-induced skin reaction.
A gene mapping study indicated the implicated genes were INHBB, TFCP2L1, and PTPN4. INHBB encodes a member of transforming growth factor-beta (TGF-β) superfamily proteins. It was reported to suppress anoikis resistance and migration in NPC [30]. As indicated in Fig. 5, it is a key modulator of inflammation by regulating TGF-β/Smad/nuclear factor kappa B (NF-κB) axis. PTPN4 belongs to PTPs enzyme family, which hydrolytically removes phosphate groups from proteins. It was reported that PTPN4 was a signaling molecule of several important pathways, including signal transducer and activator of transcription 3 (STAT3), toll like receptor 4 (TLR4), mitogen-activated protein kinase 1 (MAPK1), etc. [31–34]. TFCP2L1 is a transcription regulating factor and is reported to play key roles in inflammation by regulating KLF transcription factor 4 (KLF4)/ras homolog family member F (RHOF)/NF-κB pathway [35]. Although there is no evidence that shows that INHBB, TFCP2L1, and PTPN4 are directly involved in skin reaction, their regulated signaling pathways and cellular processes are widely reported to be correlated with inflammation as mentioned above [36, 37]. We speculate that this is the possible mechanisms of 2q14.2 loci mutation correlated with patients’ skin reaction.

Dysphagia is also an important common toxicity of radiotherapy in NPC patients. Previously, no genetic variants were reported to be correlated with this toxicity. We identified that rs584547 was a risk variant of dysphagia for the first time. Gene mapping analysis showed that this SNP may regulate SYT8 transcription. It is reasonable to speculate that it may exert function by affecting SYT8 gene expression [38]. This gene encodes a member of the synaptotagmin protein family, which is important in neurotransmission. A recent whole-exome sequencing analysis discovered that a SNP in this gene is correlated with irritable bowel syndrome and depressive disorder in the Chinese population [39]. It was also reported that SYT8 inhibited p63, forkhead box O3 (FOXO), and p53 by regulating sirtuin 1 (SIRT1), which in turn affected cellular processes of inflammation, salivary gland secretion, and damaged DNA [40, 41] (Fig. 5). It is possible that SYT8 mediated those processes and neurotransmissions to affect dysphagia. Thus, the rs584547 mutation regulates SYT8 expression and radiotherapy induced dysphagia.

Fig. 5 The potential molecular mechanisms of correlation between five susceptibility SNPs and toxicities. Rs6711678, rs4848597, rs4848598, rs2091255 implicated expression of INHBB, which regulates TGF-β/Smad/NF-κB axis. In addition, 3D chromatin interaction indicated that they interacted with TFCP2L1 and PTPN4. PTPN4 belongs to the PTP enzyme family, which hydrolytically removes phosphate groups from proteins. PTPN4 has been reported to be a signaling molecule of STAT3. TFCP2L1 is a transcription regulating factor and reported to play key roles in regulating KLF4/RHOF/NF-κB pathway. Finally, all three targeted proteins regulate NF-κB, which is a key modulator of inflammation, and correlate with skin reaction toxicity. Rs584547 was very closely located upstream of SYT8 and showed a proximal transcriptional regulation function on this gene. It was reported that SYT8 inhibited p63, FOXO, and p53 by regulating SIRT1, which in turn affected cellular processes of inflammation, DNA damage, and salivary gland secretion. SYT8 may mediate those processes to affect dysphagia. INHBB: inhibin subunit beta B, TGF-β: transforming growth factor-beta, Smad: SMAD family member 2, kBα: NF-κB inhibitor alpha, NF-κB: nuclear factor kappa B, STAT3: signal transducer and activator of transcription 3, SYT8: synaptotagmin 8, TFCP2L1: transcription factor CP2 like 1, PTPN4: protein tyrosine phosphatase non-receptor type 4, KLF4: KLF transcription factor 4, RHOF: ras homolog family member F, FOXO: forkhead box O, SIRT1: sirtuin 1.
Radiogenomics is committed to finding genetic biomarkers for prediction of radiotherapeutic effectiveness and safety. In our study, all five loci were newly discovered. This result provided more evidence to support that GWAS is a powerful tool to discover novel radiogenomic biomarkers. To explore the potential ability of these SNPs in clinic toxicity prediction, we established multivariable logistic regression models integrating both genetic and clinical factors. The ROC AUCs reached 0.657 and 0.788 for skin reaction and dysphagia, respectively. These variants substantially improved the accuracy of models. Although their performance still needs to be improved due to the limited contribution of five SNPs, we speculate that formulating a more accurate predictive model incorporating more genetic variants could be implemented in the clinic.

Some limitations should be noted while interpreting our data. First, both our genetic variant and prediction models warrant replication in larger and other cohorts. Second, the ORs associated with all five SNPs ranges from 1.74 to 4.20, indicating that contribution of these variants to the toxicities has limits. More genetic or other factors may be waiting to be discovered. Finally, the detailed mechanisms of five SNPs correlated with toxicity still need to be clarified in vitro. It is difficult to mimic skin reaction and dysphagia toxicity in cell and animal models. These studies were absent in the current study.

Conclusion

We conducted a two-stage GWAS study to identify genetic variants associated with five major radiotherapy acute toxicities (skin reaction, dysphagia, oral mucositis, salivary gland toxicity, and myelosuppression) in NPC patients. We found that rs6711678, rs4848597, rs4848598, and rs2091255 on chromosome 2q14.2 and rs584547 were novel risk loci for skin reaction and dysphagia. They could be used to optimize the treatment strategies to reduce the acute toxicities in NPC patients.

Acknowledgments

We would like to thank UNIWINSI INC (New York) for editing the manuscript.

Authors’ contributions

Ji-Ye Yin, Cheng-Xian Guo designed and guided the experiments. Yang Wang, Bi-Wen Hu, Yu-Ling Huang, Qiao-Li Lv, Xiao-Xue Xie, Wei-Hua Huang, Wei Zhang, Jin-Gao Li collected the samples, Yang Wang, Fan Xiao, Yi Zhao conducted the experiments. Ji-Ye Yin, Chen-Xue Mao, Lu-Lu Yu, Lei-Yun Wang, Qi Xiao, Rong Liu, Xi Li performed the data analyses. The manuscript was written by Yang Wang, Ji-Ye Yin, and revised by Howard L McLeod. All authors reviewed the manuscript. The author(s) read and approved the final manuscript.

Funding

This work was supported by the National Natural Science Foundation of China (82073943, 81773823 and 81974511), the Scientific and Technological Project of Changsha (kq200417), the Innovation and Talent Cultivation Project of the Third Xiangya Hospital of Central South University (YY202110), the Open Fund for Scientific Research of NHK Key Laboratory of Personalized Diagnosis and Treatment of Nasopharyngeal Carcinoma (2021NPCK01) and Hunan Cancer Hospital Climb Plan (YFZ202011).

Availability of data and materials

The datasets supporting the conclusions of this article are included within the article and its additional files.
Declarations

Ethics approval and consent to participate
The study protocol was approved by the Ethics Committee of Jiangxi Province Tumor Hospital and Hunan Cancer Hospital. All subjects were provided with written informed consents.

Consent for publication
All authors have agreed to the contents of the manuscript in its submitted form and have no conflict of interest in this manuscript.

Competing interests
The authors declare no competing interest.

Author details
1Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410078, P.R. China. 2Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacoepidemiology, Changsha 410078, P.R. China. 3Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, 110 Xiangya Road, Changsha 410078, P.R. China. 4National Clinical Research Center for Geriatric Disorders, 87 Xiangya Road, Changsha 410008, Hunan, PR. China. 5Department of General Practice, Shenzhen People’s Hospital (The Second Clinical Medical College, Jinan University, The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen 518020, Guangdong, PR China. 6Geriatric Oncology Consortium, Tampa, FL 33612, USA. 7USF Taneja College of Pharmacy, Tampa, FL 33612, USA. 8Center of Clinical Pharmacology, the Third Xiangya Hospital, Central South University, Changsha 410013, Hunan, P.R. China. 9Department of Radiation Oncology, Jiangxi Cancer Hospital of Nanchang University, Nanchang 330029, PR. China. 10National Health Commission (NHC) Key Laboratory of Personalized Diagnosis and Treatment of Nasopharyngeal Carcinoma (Jiangxi Cancer Hospital of Nanchang University), Nanchang 330029, PR. China. 11Department of Radiotherapy, Hunan Provincial Tumor Hospital and Affiliated Tumor Hospital of Xiangya Medical School, Central South University, Changsha 410013, PR. China. 12Hunan Key Laboratory of Precise Diagnosis and Treatment of Gastrointestinal Tumor, Changsha 410078, P.R. China.

Received: 17 May 2022 Accepted: 25 July 2022 Published online: 23 August 2022

References
1. Chen YP, Chan A, Le QT, Blanchard P, Sun Y, Ma J. Nasopharyngeal carcinoma. Lancet. 2019;394(10192):64–80.
2. Chang ET, Ye W, Zeng YX, Adami HO. The evolving epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomark Prev. 2021;30(6):1035–47.
3. Kerns SL, Ostrer H, Rosenstein BS. Radiooncogenomics: using genetics to identify cancer patients at risk for development of adverse effects following radiotherapy. Cancer Discov. 2014;4(2):155–65.
4. Liang SB, Wang Y, Hu XF, He SS, Yang XL, Liu LZ, et al. Survival and toxicity of IMRT based on the RTOG protocols in patients with nasopharyngeal carcinoma from the endemic regions of China. J Cancer. 2017;8(18):3718–24.
5. Kerns SL, Fachal L, Dorfling L, Barnett GC, Baron A, Peterson DR, et al. Radiooncogenomics consortium genome-wide association study Meta-analysis of late toxicity after prostate Cancer radiotherapy. J Natl Cancer Inst. 2020;112(2):179–90.
6. Barnett GC, Thompson D, Fachal L, Kerns S, Talbott C, Elliott RM, et al. A genome wide association study (GWAS) providing evidence of an association between common genetic variants and late radiotherapy toxicity. Radiother Oncol. 2014;111(2):178–85.
7. Fachal L, Gomez-Caamano A, Barnett GC, Peleteiro P, Carballo AM, Calvo-Crespo P, et al. A three-stage genome-wide association study identifies a susceptibility locus for late radiotherapy toxicity at 2q24.1. Nat Genet. 2014;46(8):891–4.
8. Wang TM, Shen GP, Chen MY, Zhang JB, Sun Y, He J, et al. Genome-wide association study of susceptibility loci for radiation-induced brain injury. J Natl Cancer Inst. 2019;111(6):620–8.
9. Yang DW, Wang TM, Zhang JB, Li XZ, He YQ, Xiao R, et al. Genome-wide association study identifies genetic susceptibility loci and pathways of radiation-induced acute oral mucositis. J Transl Med. 2020;18(1):224.
10. Cox JD, Stetz J, Paiak TF. Toxicity criteria of the radiation therapy oncology group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31(5):1341–6.
11. Therasse P, Arbuck SG, Eisenhauer EA, Wanders, J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205–16.
12. Howie BN, Donnelly P, Marchini J. A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. PLoS Genet. 2009;5(6):e1000522.
13. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81(3):559–75.
14. Pruim RJ, Welch RP, Sanna S, Teslovich TM, Chines PS, Gliedt TP, et al. LocusZoom: regional visualization of genome-wide association scan results. Bioinformatics. 2011;26(18):2336–7.
15. Watanabe K, Taekesien E, van Bochoven A, Posthuma D. Functional mapping and annotation of genetic associations with FUMA. Nat Commun. 2017;8(11):8182.
16. Guo L, Du Y, Chang S, Zhang K, Wang J. rSNPBase: a database for curated regulatory SNPs. Nucleic Acids Res. 2014;42(Database issue):D1033–9.
17. Chiu SW, O’Reilly PF. PhSlize-2: polygenic risk score software for biobank-scale data. Genascience. 2019;8(7):giz082.
18. Wang LY, Cui JJ, Liu Y, Guo AX, Zhao ZY, Liu YZ, et al. Gene-gene and gene-environment interaction data for platinum-based chemotherapy in non-small cell lung cancer. Sci Data. 2018;5:180284.
19. Wang Y, Xiao F, Chen Y, Xiao LD, Wang LY, Zhan Y, et al. Analytics of the clinical implementation of pharmacogenomics testing in 12 758 individuals. Clin Transl Med. 2021;11(11):e586.
20. Werbrouck J, De Ruyck K, Duprez F, Veldeman L, Claes K, Van Eijkeren M, et al. Acute normal tissue reactions in head-and-neck cancer patients treated with IMRT: influence of dose and association with genetic polymorphisms in DNA DSB repair genes. Int J Radiat Oncol Biol Phys. 2009;73(4):1187–95.
21. Alsbeih G, Al‑Harbi N, Al‑Hadyan K, El‑Sebaie M, Al‑Raihi N. Association between normal tissue complications after radiotherapy and polymorphic variations in TGFB1 and XRCC1 genes. Radiat Res. 2010;173(4):505–11.
22. Venkatesh GH, Manjunath VB, Mumbrekad KD, Negi H, Fernandes DJ, Sharan K, et al. Polymorphisms in radio-responsive genes and its association with acute toxicity among head and neck cancer patients. PLoS One. 2014;9(3):e89079.
23. Naderi E, Crijns A, Steenbakkers R, van den Hoek J, Boezen HM, Alizadeh BZ, et al. A two-stage genome-wide association study of radiation-induced acute toxicity in head and neck cancer. J Transl Med. 2021;19(1):481.
24. LI H, You Y, Lin C, Zheng M, Hong C, Chen J, et al. XRCC1 cordon 399Gln polymorphism is associated with radiotherapy-induced acute dermatitis and mucositis in nasopharyngeal carcinoma patients. Radiat Oncol. 2013;8:31.
25. Raturi V, Hojo H, Bhatt M, Suhel M, Wu CT, Bei Y, et al. Prospective evaluation of XRCC1-Arg194Trp polymorphism as bio-predictor for clinical outcome in locally advanced laryngeal cancer undergoing cisplatin-based chemoradiation. Head Neck. 2020;42(5):1045–56.
26. Lee E, Eum SY, Siffer SH, Martin ER, Takeda C, Wright JL, et al. Association between polymorphisms in DNA damage repair genes and radiation therapy-induced early adverse skin reactions in a breast cancer population: a polygenic risk score approach. Int J Radiat Oncol Biol Phys. 2020;106(5):948–57.
27. Terrazzino S, Cagnini S, Deantonio L, Pisani C, Masini L, Cannonico PL, et al. Impact of ATM rs1801516 on late skin reactions of radiotherapy for breast cancer: evidences from a cohort study and a trial sequential meta-analysis. PLoS One. 2019;14(11):e225685.
28. Mumbrekar KD, Bola SS, Kabekkodu SP, Fernandes DJ, Vadhiraja BM, Suga T, et al. Genetic variants in CD44 and MAT1A confer susceptibility to acute skin reaction in breast cancer patients undergoing radiation therapy. Int J Radiat Oncol Biol Phys. 2017;97(1):118–27.
29. Zhao J, Zhi Z, Zhang M, Li Q, Li J, Wang X, et al. Predictive value of single nucleotide polymorphisms in XRCCL1 for radiation-induced normal tissue toxicity. Onco Targets Ther. 2018;11:3901–18.
30. Zou G, Ren B, Liu Y, Fu Y, Chen P, Li X, et al. Inhibin B suppresses anoikis resistance and migration through the transforming growth factor-beta signaling pathway in nasopharyngeal carcinoma. Cancer Sci. 2018;109(1):3416–27.
31. Zhang BD, Li YR, Ding LD, Wang YY, Liu HY, Jia BQ. Loss of PTPN4 activates STAT3 to promote the tumor growth in rectal cancer. Cancer Sci. 2019;110(7):2258–72.
32. Huai W, Song H, Wang L, Li B, Zhao J, Han L, et al. Phosphatase PTPN4 preferentially inhibits TRIF-dependent TLR4 pathway by dephosphorylating TRAM. J Immunol. 2015;194(9):4458–65.
33. Maisonneuve P, Caillet-Saguy C, Vaney MC, Bibi-Zainab E, Sawyer K, Raynal B, et al. Molecular basis of the interaction of the human protein tyrosine phosphatase non-receptor type 4 (PTPN4) with the mitogen-activated protein kinase p38gamma. J Biol Chem. 2016;291(32):16699–708.
34. Liu X, Dong Y, Song D. Inhibition of microRNA-15b-5p attenuates the progression of Oral squamous cell carcinoma via modulating the PTPN4/STAT3 Axis. Cancer Manag Res. 2020;12:10559–72.
35. Kotarba G, Krzywinska E, Grabowska AI, Taracha A, Wlanowski T. TFCP2/TFCP2L1/UBP1 transcription factors in cancer. Cancer Lett. 2018;420:72–9.
36. Kiang J, Olibasi AO. Radiation: a poly-traumatic hit leading to multi-organ injury. Cell Biosci. 2019;9:25.
37. Liu Y, Peng X, Li H, Jiao W, Peng X, Shao J, et al. STAT3 inhibitor Napabucasin inhibits tumor growth and cooperates with proteasome inhibition in human ovarian cancer cells. Recent Pat Anticancer Drug Discov. 2021;16(3):350–62.
38. Wu CC, Brugeaud A, Seist R, Lin HC, Yeh WH, Pettrillo M, et al. Altered expression of genes regulating inflammation and synaptogenesis during regrowth of afferent neurons to cochlear hair cells. PLoS One. 2020;15(10):e258578.
39. Zhu S, He M, Liu Z, Qin Z, Wang Z, Duan L. Shared genetic susceptibilities for irritable bowel syndrome and depressive disorder in Chinese patients uncovered by pooled whole-exome sequencing. J Adv Res. 2020;23:1113–21.
40. Fu Z, Liang X, Shi L, Tang L, Chen D, Liu A, et al. SYT8 promotes pancreatic cancer progression via the TNNI2/ERalpha/SIRT1 signaling pathway. Cell Death Discov. 2021;7(1):390.
41. Chen C, Zhou M, Ge Y, Wang X. SIRT1 and aging related signaling pathways. Mech Ageing Dev. 2020;187:111215.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.